Navigation Links
DMP for diabetes type 1: guidelines indicate some need for revision

This press release is available in German.

On 22 August 2011, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with diabetes mellitus type 1. The aim of the report is to identify those recommendations from current guidelines of high methodological quality that may be relevant for the planned revision of the corresponding disease management programme (DMP). According to the results of the report, there is no compelling need for revision of any part of the DMP. However, IQWiG identified various aspects that could be supplemented and specified.

Evidence was documented in detail

One of the responsibilities of IQWiG specified by law (Social Code Book V) is to develop and issue recommendations for DMPs. In the commission now completed, which was awarded by the Federal Joint Committee (G-BA), IQWiG systematically searched for new guidelines, assessed their methodological quality, and extracted relevant recommendations on the diagnosis and treatment of diabetes mellitus type 1, its accompanying diseases and late complications, as well as on the cooperation of health care sectors. In addition, the Institute documented how highly the guideline authors graded the robustness of the recommendations. However, the sources of the recommendations were not examined again; this is where IQWiG's guideline appraisals and benefit assessments differ.

No contradictions between the DMP and current recommendations

A total of 23 German and international guidelines containing recommendations on the treatment of diabetes type 1 were included. As the analysis showed, the recommendations in the guidelines are, by and large, consistent with the specifications of the DMP. No contradictions in content concerning the DMP requirements were found. The Director of IQWiG, Professor Dr med. Jrgen Windeler, stresses that "patients with diabetes mellitus type 1 can thus be sure that the current DMP is consistent with the current status of medical knowledge on all main points.

Some potential additional recommendations identified for the DMP

However, in these guidelines recommendations were found on a total of 8 subject areas from which, after examination and discussion, the need may arise to update and supplement the German DMP for diabetes mellitus type 1.

For example, some guidelines recommend higher blood glucose levels (increase in HbA1C) in patients susceptible to hypoglycaemia, as well as dietary advice and therapy. Neither item has so far been included in the legal regulations on the DMP for diabetes mellitus type 1. Moreover, while the DMP currently mentions only the diagnosis and treatment of diabetic retinopathy, guidelines also include recommendations on the treatment of clinically relevant macula oedema. These three aspects of treatment could in future be additionally considered in the DMP.

It is the Institute's responsibility, first of all to identify differences between guideline recommendations and the DMP. The Federal Joint Committee then examines whether these differences should actually lead to a revision of the DMP for diabetes mellitus type 1.


Contact: Dr. Anna-Sabine Ernst
Institute for Quality and Efficiency in Health Care

Related medicine news :

1. Neighborhood socioeconomic status and diabetes
2. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
3. International Diabetes Federation awards $2 million to 9 global diabetes research projects
4. Diabetes drug ups risk for bone fractures in older women
5. Diabetes Drugs Avandia, Actos Tied to Fractures in Women
6. Fishy Smell May Keep Patients From Diabetes Drug
7. Small Increase in Diabetes Risk Noted in Statin Patients
8. FDA Approved Diabetes Drug Despite Hints at Cancer Risk
9. Remove Diabetes Drug Avandia From Market: FDA Reports
10. Remove Diabetes Drug Avandia From Market: FDA Documents
11. Excessive Weight Gain During Pregnancy Raises Gestational Diabetes Risk
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... addition of the "Veterinary Equipment and Disposables ... to 2020" report to their offering. ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics Holdings, ... company, announces it has filed an Investigational New Drug ... (FDA) for the Company,s lead fully human antibody product ... acceptance, MabVax plans to initiate the Phase I clinical ... --> The planned Phase I trial ...
Breaking Medicine Technology: